Magic Mushrooms SeattleThe Seattle psilocybin almanac
ContentsCloseMore entries

Psilocybin research in Seattle: a history and register

Seattle's psilocybin research includes a state-ordered University of Washington trial, UW and Fred Hutch studies of group therapy for people with cancer, a VA trial site and industry trials at clinics in Seattle, Bellevue and Everett. As of November 2, 2026, 11 trials of psilocybin or a psilocin analog list a Washington site, and the state-ordered trial has stopped recruiting but hasn't published results.

Products

From the shop our team runs, My Mushroom Dispensary. Adults 21+ only.

Last checked by the Magic Mushrooms Seattle editors

Drawing of a brass microscope, glass flasks, a test tube rack and books on a desk by a rain-streaked window, with brick university buildings and evergreen trees outside
Plate 1.AI illustration in the style of a wood engraving: a microscope and lab glassware at a rainy window, with brick university halls and evergreens beyond.
In this entry
  1. Seattle's place in psilocybin research
  2. The state pilot
  3. Seattle's research groups
  4. Trials with Washington sites
  5. Before the clinic
  6. The register
  7. How to read a trial record
  8. Questions people ask
  9. Sources

Seattle's place in psilocybin research

On May 9, 2023, Gov. Jay Inslee signed a law ordering the University of Washington's psychiatry department to set up a psilocybin therapy pilot for veterans and first responders; the trial that carries it out, PsiloStudy, started on June 1, 2025.1,5,6 On December 2, 2024, UW researchers published a randomized trial of 30 frontline clinicians in which psilocybin therapy lowered depression scores more than a placebo did.8 As of November 2, 2026, 10 psilocybin trials on ClinicalTrials.gov list a Washington site, plus one trial of CYB003, a psilocin analog.11

The record is older than the clinics: in May 1982, chemists published psilocybin measurements for 20 wild Northwest mushroom species.14

The state pilot

Second Substitute Senate Bill 5263 became chapter 364, Laws of 2023. A partial veto struck other sections but kept the pilot.1 The Legislature's final bill report sums up the duty:

Subject to appropriation, by January 1, 2025, the University of Washington Department of Psychiatry and Behavioral Sciences must establish and administer a Psilocybin Therapy Services Pilot Program

Washington State Legislature, Final Bill Report, 2SSB 5263, 2023

The pilot must offer psilocybin therapy, through pathways approved by the FDA, to populations including first responders and veterans aged 21 and older with PTSD, mood disorders or substance use disorders.1

The money

The 2023-25 budget, signed May 16, 2023, gave UW $1,464,000 "solely for implementation of" the bill.2 The 2025-27 budget, signed May 20, 2025, gave $730,000 more, also "solely for implementation of" the law.3 That's $2,194,000 in all. The budget lines fund the law, not PsiloStudy by name.

PsiloStudy

UW's Center for Novel Therapeutics in Addiction Psychiatry runs PsiloStudy and ties it to SB 5263.6 The registry record (NCT06853912) describes a phase 2, single-site, randomized, double-blind, placebo-controlled trial with an open-label extension, for about 40 veterans and first responders aged 21 to 65 who have both PTSD and alcohol use disorder. That's a narrower group than the law names. The primary outcome is safety.5

The law set January 1, 2025 as the deadline to establish the pilot; the registry gives June 1, 2025 as the trial's start date.1,5 Recruiting ended on June 26, 2026.6 Primary completion was estimated for November 1, 2026, and the record, last updated on August 13, 2026, still gives an estimated enrollment rather than an actual count.5 As of November 2, 2026, we found no posted or published results.

Seattle's research groups

UW addiction psychiatry

The Center for Novel Therapeutics in Addiction Psychiatry, led by Nathan Sackett, was announced as an official UW research center on March 30, 2023, to combine "psychedelic compounds with evidence-based behavioral interventions" against addiction.7 The 2024 supplemental budget gave it $250,000 for "an initial study of ibogaine assisted therapy",4 and the 2025-27 budget added $10,000 for a UW cohort study of ibogaine-assisted therapy for opioid use disorder.3 We found no registry record for either ibogaine study.

UW Medicine and Fred Hutch

Palliative care physician Anthony Back leads a group at UW's Department of Medicine and Fred Hutch. In his frontline clinician trial, depression scores (MADRS) fell 21.3 points with psilocybin therapy and 9.3 with a niacin placebo at day 28, a 12-point difference; burnout didn't differ significantly.8 The team then gave psilocybin therapy in groups, at retreats, to people with metastatic cancer. The phase 1/2 study (NCT05847686) enrolled 55 people, and 52 completed it.11 Fred Hutch reported on March 25, 2026 that across its eight retreats, anxiety and depression fell by clinically meaningful amounts and stayed lower for at least six months.9 A second-retreat study (PMID 42058096) and a phase 2a trial (NCT07336238) followed, along with a small MDMA pilot for pathological narcissism (NCT06565494).11

VA Puget Sound

VA Puget Sound in Seattle is one of five sites in PIVOT, a VA phase 3 trial of psilocybin for veterans with treatment-resistant depression. It began on August 3, 2026, plans 240 participants and lists the Seattle site as recruiting.10

Elsewhere

Allen Institute scientists co-authored a mouse study of psilocybin and brain wiring (PMID 41352354). In registry and PubMed searches we found no psychedelic trial from Kaiser Permanente Washington or Seattle Children's, and no psilocybin study from either. Microdosing has its own entry, the Stamets stack.

Trials with Washington sites

Companies and nonprofits run multi-site trials at two Puget Sound research sites: Seattle Neuropsychiatric Treatment Center, in Seattle and Bellevue, and Core Clinical Research in Everett. Between them they host 11 of the register's 12 multi-site trials run by companies and nonprofits.11

Phase 3 trials run by companies and nonprofits with a Puget Sound site, ClinicalTrials.gov, November 2, 2026
What it testsSiteStatus
COMP360 psilocybin, one administration, treatment-resistant depressionEverettCompleted
COMP360 psilocybin, two administrations, treatment-resistant depressionSeattleActive, not recruiting
Usona psilocybin (uAspire), major depressionBellevueActive, not recruiting
CYB003, a psilocin analog, major depressionSeattle; EverettRecruiting in Seattle
DT120 or MM120 (LSD), generalized anxiety, two trials (Voyage, Panorama)Seattle; EverettActive, not recruiting
DT120 (LSD), major depressionSeattleNot yet recruiting here
TSND-201 (methylone), PTSDSeattleRecruiting

Phase 2 trials at these sites include VLS-01, which its developer atai describes as a DMT film,12 and RE104, which Reunion Neuroscience describes as a prodrug of 4-OH-DiPT.13 In Vancouver, Washington, the Portland VA campus hosts a psilocybin study for methamphetamine use disorder. Records give enrollment for the whole trial, not for each site.

Before the clinic

The older Washington records we could confirm concern wild mushrooms. On Halloween weekend 1976, about 120 people met at a Washington state park for what the Puget Sound Mycological Society's bulletin called "The First Psychotropic Mushroom Foray" (PSMS bulletin No. 127; more in our news post). Mycologia's November to December 1976 issue carried Gastón Guzmán and Jonathan Ott's description of a new Psilocybe species from the Pacific Northwest (PMID 1034878). The Second International Conference on Hallucinogenic Mushrooms met near Port Townsend on October 27 to 30, 1977, and Seattle's Madrona Publishers printed extracts in 1978.16

The chemistry has an Olympia connection. Michael Beug taught chemistry and mycology at The Evergreen State College for 32 years.15 With Jeremy Bigwood he published a method for measuring psilocybin in 1981 (PMID 7194879) and, in May 1982, tests of 20 wild Northwest species: seven contained psilocybin, and levels varied more than sevenfold between collections.14 We found no primary record of 1950s or 1960s LSD research at UW or Western State Hospital, so the register lists none. The history, timeline and wild species entries carry the wider story.

The register

58 records, grouped by kind and newest first. Trial status is the registry's as of November 2, 2026, and a paper's year is when it first appeared, online or in print. Trial doses are left out. Filter, search, open a record or download the data.

58 records.

  1. State budget 2025-27: UW psilocybin appropriationPrograms and centers: Washington Legislature, appropriated to the University of Washington, 2025
    Status
    Enacted May 20, 2025; unchanged in the 2026 supplemental budget (ESSB 5998)
    Details
    $730,000 from the workforce education investment account, provided solely for implementation of chapter 364, Laws of 2023 (psilocybin).
  2. State funding for a UW cohort study of ibogaine-assisted therapyPrograms and centers: University of Washington, 2025
    Studied
    Opioid use disorder in adults
    Status
    Appropriated May 20, 2025; unchanged in the 2026 supplemental; no ClinicalTrials.gov record found
    Details
    $10,000 for a prospective, randomized cohort study between July 1, 2025 and June 30, 2027 comparing ibogaine-assisted therapy at a licensed clinic in North America, followed by structured support, with treatment as usual; UW may also use private philanthropic funding.
  3. State funding for an initial UW study of ibogaine-assisted therapyPrograms and centers: University of Washington Center for Novel Therapeutics in Addiction Psychiatry, 2024
    Studied
    Ibogaine-assisted therapy (the budget text names no condition)
    Status
    Appropriated March 29, 2024; no ClinicalTrials.gov record found
    Details
    $250,000 from the opioid abatement settlement account, provided solely for an initial study of ibogaine-assisted therapy.
  4. Psilocybin Therapy Services Pilot Program (2SSB 5263)Programs and centers: University of Washington Department of Psychiatry and Behavioral Sciences, 2023
    Studied
    PTSD, mood disorders or substance use disorders, in populations including first responders and veterans aged 21 and older
    Status
    In law since July 23, 2023; carried out through PsiloStudy
    Details
    Chapter 364, Laws of 2023, signed with a partial veto on May 9, 2023, requires UW, subject to appropriation, to offer psilocybin therapy through FDA-approved pathways by January 1, 2025, with outreach to groups less likely to be included in research.
  5. State budget 2023-25: UW psilocybin appropriationPrograms and centers: Washington Legislature, appropriated to the University of Washington, 2023
    Status
    Enacted May 16, 2023; unchanged in the 2024 supplemental budget
    Details
    $1,464,000 from the workforce education investment account, provided solely for implementation of 2SSB 5263 (the provisos do not name PsiloStudy).
  6. UW Center for Novel Therapeutics in Addiction Psychiatry (NTAP)Programs and centers: University of Washington Department of Psychiatry and Behavioral Sciences, 2023
    Studied
    Alcohol, opioid and tobacco use disorders
    Status
    Official UW research center as of a March 30, 2023 announcement; UW's Addictions, Drug and Alcohol Institute announced on February 2, 2026 that NTAP had joined it
    Details
    Studies psychedelic compounds combined with behavioral interventions for addiction; runs the state-mandated PsiloStudy and was named in the 2024 budget for the state's ibogaine study money; director Nathan Sackett.
    Record
    NTAP
  7. Washington Psilocybin Task Force final reportPrograms and centers: Washington State Health Care Authority with the Center for Evidence-based Policy (OHSU), 2023
    Studied
    Research gaps for UW and WSU
    Status
    Final report delivered December 1, 2023
    Details
    Set up under 2SSB 5263; ranked research gaps for state-funded work, with racial diversity of trial participants first among population gaps, then people with co-occurring conditions, then larger samples.
  8. PIVOT: psilocybin for veterans with treatment-resistant depressionClinical trials: VA Office of Research and Development; site at VA Puget Sound, Seattle, 2026
    Studied
    Treatment-resistant depression in veterans, with or without PTSD
    Status
    Recruiting
    Details
    Phase 3 randomized controlled trial at five VA sites; 240 participants planned; Seattle site recruiting; primary completion estimated December 2, 2030.
  9. Group retreat psilocybin therapy for anxiety and depression in metastatic or incurable cancer (phase 2a)Clinical trials: University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle, 2026
    Studied
    Anxiety and depression with metastatic solid tumors or incurable blood cancers
    Status
    Active, not recruiting
    Details
    Phase 2a group-retreat study; 16 enrolled; primary completion estimated December 1, 2026; the record says the psilocybin is provided by Filament Health.
  10. Group retreat psilocybin therapy for clinicians with loss of meaning in their work and depressionClinical trials: University of Washington; no site listed yet, 2026
    Studied
    Depression and loss of meaning in work among healthcare clinicians
    Status
    Not yet recruiting
    Details
    Phase 2 sequential study of preparation for group retreat therapy; 72 participants planned; start estimated for June 2026, but the record, last updated May 4, 2026, still lists the study as not yet recruiting and names no site.
  11. Ascend: DT120 (LSD) for major depressive disorderClinical trials: Definium Therapeutics US, Inc.; sites in Seattle and Vancouver, WA, 2026
    Studied
    Major depressive disorder
    Status
    Recruiting
    Details
    Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 165 planned across 30 sites; both Washington sites listed as not yet recruiting.
  12. EMPOWER-1: TSND-201 (methylone) for PTSDClinical trials: Transcend Therapeutics; site in Seattle (Seattle Neuropsychiatric Treatment Center), 2026
    Studied
    PTSD
    Status
    Recruiting
    Details
    Phase 3, randomized, double-blind, placebo-controlled; 300 planned across 37 sites; Seattle site recruiting.
  13. PsiloStudy: psilocybin with psychological support for veterans and first responders with PTSD and alcohol use disorderClinical trials: University of Washington Center for Novel Therapeutics in Addiction Psychiatry; site in Seattle, 2025
    Studied
    PTSD with alcohol use disorder in military veterans and first responders
    Status
    Active, not recruiting
    Details
    Phase 2, single site, randomized, double-blind and placebo-controlled, with an open-label extension; about 40 participants aged 21 to 65 planned; primary outcome is safety; primary completion estimated November 1, 2026.
  14. EMBRACE: CYB003, a deuterated psilocin analog, for major depressive disorderClinical trials: Cybin IRL Limited; sites in Seattle and Everett, 2025
    Studied
    Major depressive disorder
    Status
    Recruiting
    Details
    Phase 3, multicenter, double-blind, randomized; compares two dose levels of CYB003 with placebo; 330 planned across 79 sites; Seattle site recruiting, Everett site not yet recruiting.
  15. Panorama: MM120 (LSD) for generalized anxiety disorderClinical trials: Definium Therapeutics US, Inc.; site in Everett (Core Clinical Research), 2025
    Studied
    Generalized anxiety disorder
    Status
    Active, not recruiting
    Details
    Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 245 enrolled across 36 sites; primary completion August 13, 2026.
  16. RE104 for adjustment disorder in cancer and other medical illnessClinical trials: Reunion Neuroscience; site in Seattle (Seattle Neuropsychiatric Treatment Center), 2025
    Studied
    Adjustment disorder in people with cancer or other medical illness
    Status
    Recruiting
    Details
    Phase 2, randomized, double-blind, dose-controlled; 100 planned across 32 sites; Seattle site recruiting; primary completion estimated November 2026.
  17. Second group psilocybin retreat for partial responders with cancer-related anxietyClinical trials: University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle, 2024
    Studied
    Anxiety in people with metastatic cancer who partly responded to a first retreat
    Status
    Completed
    Details
    Phase 1 single-arm study; 15 enrolled; completed September 30, 2025; published in 2026 (PMID 42058096).
  18. uAspire: psilocybin for major depressive disorderClinical trials: Usona Institute; sites in Bellevue and Vancouver, WA, 2024
    Studied
    Major depressive disorder
    Status
    Active, not recruiting
    Details
    Phase 3, randomized, double-blind, multicenter; 238 enrolled across 29 sites; primary completion January 5, 2026; study completion estimated January 30, 2027.
  19. MDMA-assisted therapy for pathological narcissismClinical trials: University of Washington; site in Seattle, 2024
    Studied
    Pathological narcissism
    Status
    Active, not recruiting
    Details
    Early phase 1, open-label pilot; 12 enrolled; primary completion was estimated for August 15, 2026, and the record was last updated in February 2026.
  20. Voyage: DT120 (LSD) for generalized anxiety disorderClinical trials: Definium Therapeutics US, Inc.; site in Seattle (Seattle Neuropsychiatric Treatment Center), 2024
    Studied
    Generalized anxiety disorder
    Status
    Active, not recruiting
    Details
    Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 214 enrolled across 34 sites; the registry lists MM120 and lysergide tartrate among the drug's other names.
  21. ELUMINA: VLS-01 buccal film for treatment-resistant depressionClinical trials: atai Therapeutics; site in Bellevue (Seattle Neuropsychiatric Treatment Center), 2024
    Studied
    Treatment-resistant depression
    Status
    Completed
    Details
    Phase 2, multicenter, randomized, double-blind, placebo-controlled with repeated administrations; 142 enrolled across 48 sites; completed October 16, 2026. The developer describes VLS-01 as a DMT film; the registry record does not name the compound.
  22. RE104 for postpartum depressionClinical trials: Reunion Neuroscience; site in Seattle, 2024
    Studied
    Postpartum depression
    Status
    Completed
    Details
    Phase 2, multicenter, randomized, double-blind, dose-controlled; 84 enrolled across 38 sites; completed June 16, 2025. The developer describes RE104 (luvesilocin) as a prodrug of 4-OH-DiPT, a 5-HT2A agonist; the registry record does not name the compound.
  23. IMPACT-2: methylone for PTSDClinical trials: Transcend Therapeutics; site in Bellevue (Seattle Neuropsychiatric Treatment Center), 2024
    Studied
    PTSD
    Status
    Completed
    Details
    Phase 2 study; 62 enrolled across 12 sites; completed September 23, 2025; results posted on the registry.
  24. Group retreat psilocybin therapy for cancer-related anxiety (phase 1/2)Clinical trials: University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle, 2023
    Studied
    Anxiety in people with metastatic cancer
    Status
    Completed
    Details
    Phase 1/2 group-retreat study; 55 started and 52 completed; registry results list 3 participants with serious adverse events and no instances of unattended psilocybin-related distress.
  25. COMP360 psilocybin, two administrations, for treatment-resistant depressionClinical trials: COMPASS Pathways; site in Seattle (Seattle Neuropsychiatric Treatment Center), 2023
    Studied
    Treatment-resistant depression
    Status
    Active, not recruiting
    Details
    Phase 3, multicenter, randomized, double-blind and controlled; 572 enrolled across 116 sites; primary completion November 13, 2025; no results posted on the registry as of November 2, 2026.
  26. COMP360 psilocybin, single administration, for treatment-resistant depressionClinical trials: COMPASS Pathways; site in Everett (Core Clinical Research), 2023
    Studied
    Treatment-resistant depression
    Status
    Completed
    Details
    Phase 3, multicenter, randomized, double-blind and placebo-controlled; 258 enrolled across 40 sites; completed April 15, 2026; no results posted on the registry as of November 2, 2026.
  27. Group-MVP: group MDMA therapy for veterans with PTSDClinical trials: Portland VA Research Foundation; site at the Portland-Vancouver VA, Vancouver, WA, 2023
    Studied
    PTSD in veterans
    Status
    Completed
    Details
    Phase 1/2 open-label feasibility and safety study; 23 enrolled; completed March 14, 2025.
  28. SM-001, an ayahuasca-type plant decoction, in healthy adultsClinical trials: Advanced Integrative Medical Science (AIMS) Institute; site in Seattle, 2023
    Studied
    Healthy adults (the record also lists major depression and PTSD)
    Status
    Unknown
    Details
    Phase 1 open-label study; 12 participants planned; start estimated for October 2023; the record has not been updated since July 2023, so whether the study ran is not known.
  29. Psilocybin therapy for frontline clinicians with depression after COVID-19 workClinical trials: University of Washington; site in Seattle, 2022
    Studied
    Depression and burnout in doctors, advanced practice clinicians and nurses
    Status
    Completed
    Details
    Randomized trial (registry lists phase 3) of psilocybin with psychotherapy against an active placebo; 30 enrolled; results posted on the registry and published in JAMA Network Open (PMID 39636638).
  30. Psilocybin-enhanced psychotherapy for methamphetamine use disorderClinical trials: Portland VA Research Foundation; site at the Portland VA campus in Vancouver, WA, 2022
    Studied
    Methamphetamine use disorder
    Status
    Active, not recruiting
    Details
    Phase 1/2 single-site study; 30 participants planned; primary completion estimated December 31, 2026.
  31. Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPublished studies: University of Washington and Fred Hutch Cancer Center, 2026
    Studied
    Anxiety and depression in metastatic cancer
    Status
    Published
    Finding
    Across eight group retreats with 52 participants, Fred Hutch's summary reports clinically meaningful drops in anxiety and depression that lasted at least six months and no unattended distress that needed the backup facilitators.
  32. A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experiencePublished studies: University of Washington and Fred Hutch Cancer Center, 2026
    Studied
    Anxiety and depression in metastatic cancer (partial responders)
    Status
    Published
    Finding
    In a single-arm study, 13 partial responders completed a second group retreat; no serious adverse events occurred, mean HADS scores fell from 15.08 to 9.00 at day 8, and 69% reached scores below the clinical threshold.
  33. Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patientsPublished studies: University of Washington, 2026
    Studied
    Body-focused preparation for psilocybin therapy in cancer
    Status
    Published
    Finding
    Hypothesis paper with no sample: proposes a framework for interoceptive preparation and a six-category taxonomy of bodily experiences reported in sessions.
  34. Ibogaine for Opioid Use Disorder: An Unrecognized RiskPublished studies: Co-authored by Nathan Sackett, the name of UW's NTAP director (the PubMed record lists no affiliations), 2026
    Studied
    Ibogaine and opioid use disorder
    Status
    Published
    Finding
    Commentary with no sample: warns that presenting ibogaine as a replacement for methadone or buprenorphine could raise overdose risk for some people with opioid use disorder.
  35. Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative reviewPublished studies: International authors including UW's Nathan Sackett, 2026
    Studied
    Negative and depressive symptoms in schizophrenia spectrum disorders
    Status
    Published
    Finding
    Narrative review with no new sample of mechanistic, animal and early clinical evidence on whether psychedelics could help these symptoms.
  36. Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 StudyPublished studies: University of Washington and Fred Hutch Cancer Center, 2025
    Studied
    Facilitation model for group psilocybin therapy in metastatic cancer
    Status
    Published
    Finding
    Technical report with no new sample: describes the trial's facilitation model, built on the anthropology of rites of passage (preparation, the psilocybin session and integration).
  37. Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approachPublished studies: University of Washington, 2025
    Studied
    Pathological narcissism
    Status
    Published
    Finding
    Theoretical paper with no sample: proposes psychoanalytically informed MDMA-assisted therapy for pathological narcissism, which the authors say is being tested in an investigator-initiated trial; UW pilot NCT06565494 lists both authors as principal investigators.
  38. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networksPublished studies: Cornell University, with co-authors at the Allen Institute for Brain Science, Seattle, 2025
    Studied
    Psilocybin and brain networks in mice
    Status
    Published
    Finding
    In mice (group sizes are in the paper, not the abstract), psilocybin rewired inputs to frontal cortex neurons in a network-specific way, and silencing a brain region during the drug session disrupted the rewiring.
  39. The void and the brainPublished studies: Allen Institute, Seattle, 2025
    Studied
    5-MeO-DMT and brain activity (EEG)
    Status
    Published
    Finding
    Commentary with no sample on an EEG study of inhaled 5-MeO-DMT that found strongly slowed brain activity without the alpha-power drop seen with other psychedelics.
  40. Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users' Patterns of Use and Perceived EffectsPublished studies: Washington State University, Pullman, 2025
    Studied
    Patterns of psychedelic use
    Status
    Published
    Finding
    An online survey of 1,486 US adults who use psychedelics found MDMA, LSD, DMT and psilocybin were the most used, most use was recreational, and average distress ratings for acute effects were low.
  41. Experimental Test of Perceptions of Psychedelics by Therapeutic and Recreational UsePublished studies: Washington State University Vancouver, 2025
    Studied
    Public perceptions of therapeutic and recreational psychedelic use
    Status
    Published
    Finding
    In an experiment with 309 participants, therapeutic use was seen as healthier than recreational use, and people with lifetime use rated both more positively.
  42. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical TrialPublished studies: University of Washington, 2024
    Studied
    Depression in frontline clinicians after COVID-19 work
    Status
    Published
    Finding
    In a randomized trial of 30 US physicians, advanced practice clinicians and nurses, depression scores (MADRS) fell 21.3 points with psilocybin therapy versus 9.3 with a niacin placebo at day 28, a 12-point difference; the burnout difference was not statistically significant.
  43. Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted TherapyPublished studies: University of Washington and Fred Hutch Cancer Center, 2024
    Studied
    Facilitator touch in group psilocybin therapy
    Status
    Published
    Finding
    Methods report from the group cancer trial: the team rewrote its rules on facilitator touch after two unexpected touch-related experiences in the first three retreats.
  44. Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative AnalysisPublished studies: Washington State University, Spokane, with UW's Center for Novel Therapeutics in Addiction Psychiatry, 2024
    Studied
    Underground psychedelic-assisted therapy practice
    Status
    Published
    Finding
    Qualitative analysis of interviews with underground guides (the abstract gives no count) found four themes, including mixed feelings about legalization: wanting more access but worrying about losing flexibility.
  45. Systematic review and rationale of using psychedelics in the treatment of cannabis use disorderPublished studies: University of Washington School of Medicine, 2023
    Studied
    Cannabis use disorder
    Status
    Published
    Finding
    Systematic review screened 305 unique records and found one primary study, using ketamine, that met its inclusion criteria.
  46. Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patientPublished studies: University of Washington Department of Psychiatry and Behavioral Sciences, 2023
    Studied
    Access to psychedelic therapy for people with addiction
    Status
    Published
    Finding
    Ethics paper with no sample: argues for equitable access to psychedelic therapy for addiction patients labeled "high-risk".
  47. Psilocybin in Palliative Care: An UpdatePublished studies: Advanced Integrative Medical Science (AIMS) Institute, Seattle, 2023
    Studied
    Psilocybin in palliative care
    Status
    Published
    Finding
    Review with no new sample of five years of psilocybin evidence in palliative care; notes short follow-up and a risk of selection bias toward healthy, white, financially privileged people.
  48. What Psilocybin Taught Me About DyingPublished studies: University of Washington, 2018
    Studied
    Palliative care
    Status
    Published
    Finding
    Essay by UW palliative care physician Anthony Back, published online November 9, 2018 (print July 2019); no abstract and no sample.
  49. Mania following use of ibogaine: A case seriesPublished studies: University of Washington Department of Psychiatry and Behavioral Sciences (co-author), 2015
    Studied
    Mania after unregulated ibogaine use
    Status
    Published
    Finding
    Case series of 3 psychiatric emergency patients with no prior bipolar diagnosis who developed mania after unregulated ibogaine use; the authors call it the first report of mania stemming from ibogaine use.
  50. A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington StatePublished studies: Washington State Patrol Toxicology Laboratory, Seattle, 2015
    Studied
    A death involving 25I-NBOMe and psilocin
    Status
    Published
    Finding
    Single-case review of a 2014 death of a 15-year-old after 25I-NBOMe and mushrooms; the manner of death was ruled accidental, from combined 25I-NBOMe and psilocin intoxication.
  51. Epidemiology of MDMA and associated club drugs in the Seattle areaPublished studies: UW Alcohol and Drug Abuse Institute, 2005
    Studied
    MDMA and club drug use in the Seattle area
    Status
    Published
    Finding
    A review of seven Seattle-area data sources (surveys, deaths, emergency department mentions and treatment admissions) found moderate MDMA use, low death and acute harm, and high suspected adulteration.
  52. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrationsEarlier research: University of Washington, Harborview Medical Center, 1998
    Studied
    Ketamine's psychedelic effects
    Status
    Published
    Details
    In 10 healthy volunteers, ketamine's psychedelic effects rose in a straight line with blood level, and hallucinogen rating scores resembled those from an earlier DMT study.
  53. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria groupEarlier research: Children's Hospital and Medical Center and University of Washington, Seattle, 1992
    Studied
    Amanita mushroom poisoning in children
    Status
    Published
    Details
    Nine children were admitted for Amanita pantherina (8) or Amanita muscaria (1) poisoning; symptoms began within 30 to 180 minutes, 4 had seizures or twitching, and all recovered.
  54. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A.Earlier research: Michael W. Beug (longtime Evergreen State College chemistry teacher) and Jeremy Bigwood, 1982
    Studied
    Psilocybin in wild Pacific Northwest mushrooms
    Status
    Published
    Details
    Of 20 wild species from seven genera tested, seven species from three genera contained psilocybin, and levels varied more than sevenfold between collections.
  55. Quantitative analysis of psilocybin and psilocin in Psilocybe baeocystis (Singer and Smith) by high-performance liquid chromatography and by thin-layer chromatographyEarlier research: Michael W. Beug (longtime Evergreen State College chemistry teacher) and Jeremy Bigwood, 1981
    Studied
    Measuring psilocybin and psilocin in Psilocybe baeocystis
    Status
    Published
    Details
    Method paper: rapid liquid chromatography and thin-layer chromatography measurement of psilocybin and psilocin in Psilocybe baeocystis.
  56. Second International Conference on Hallucinogenic Mushrooms, near Port TownsendEarlier research: Proceedings published by Madrona Publishers, Seattle, 1977
    Studied
    Hallucinogenic mushrooms of North America
    Status
    Held October 27 to 30, 1977; extracts published 1978
    Details
    Extracts from the conference were published in Seattle in 1978 as Teonanácatl: Hallucinogenic Mushrooms of North America.
  57. Description and chemical analysis of a new species of hallucinogenic Psilocybe from the Pacific NorthwestEarlier research: Gastón Guzmán and Jonathan Ott (affiliations not in the PubMed record), 1976
    Studied
    A new Psilocybe species from the Pacific Northwest
    Status
    Published
    Details
    Mycologia paper (November to December 1976 issue) that described a new hallucinogenic Psilocybe species from the Pacific Northwest and analyzed its chemistry.
  58. Psychotropic mushroom meeting at a Washington state park (the PSMS bulletin's "First Psychotropic Mushroom Foray")Earlier research: Reported by the Puget Sound Mycological Society, Seattle, 1976
    Studied
    Psychotropic mushrooms
    Status
    Held Halloween weekend 1976; reported December 1976
    Details
    The society's bulletin called it "The First Psychotropic Mushroom Foray" and reported about 120 attendees; speakers included Gastón Guzmán, Jonathan Ott, R. Gordon Wasson and Lynn Brady of the UW School of Pharmacy.

Download this data. Psilocybin and psychedelic research in Seattle and Washington: a register, 58 rows, updated November 2, 2026. Free to reuse under CC BY 4.0 with a link to this page.

How to read a trial record

The status words mean what they say: "Not yet recruiting", "Recruiting", "Active, not recruiting" (still running, closed to new people) and "Completed". "Unknown" marks a stale record, like the AIMS Institute's ayahuasca-type study (NCT05894902), untouched since July 2023.11 If any site of a multi-site trial is recruiting, federal rules require the whole trial to show "Recruiting",17 which is why the DT120 depression trial reads "Recruiting" while its Washington sites don't.

The primary completion date is when the last participant is examined or treated for the main outcome. An "estimated" date has to be changed to the actual one within 30 days of reaching it, and estimated enrollment becomes the actual count.17

Results lag. Trials covered by the federal rule, which excludes phase 1 drug studies, generally get a year after primary completion to post results, and some can take longer.17 Journals add time: UW's clinician trial (NCT05163496) reached primary completion on December 30, 2023, and its paper appeared on December 2, 2024.8,11

Questions people ask

Can I join a psilocybin study in Seattle?

As of November 2, 2026, two trials of psilocybin or a psilocin analog list a recruiting Washington site: PIVOT at VA Puget Sound, for veterans, and Cybin's CYB003 trial in Seattle.10,11 PsiloStudy stopped recruiting on June 26, 2026.6 Eligibility and contacts are on each ClinicalTrials.gov record.

Does the state pilot make psilocybin legal in Washington?

No. The law requires the pilot to offer psilocybin therapy through pathways approved by the FDA,1 and psilocybin and psilocyn remain Schedule I controlled substances under Washington law.18

Has PsiloStudy published results?

Not as of November 2, 2026. Its primary completion was estimated for November 1, 2026,5 and federal rules generally give covered trials a year after that to post results.17

Can I reuse the register?

Yes, under CC BY 4.0. Download the CSV or JSON below the list and credit Magic Mushrooms Seattle.

Sources

  1. Final Bill Report, 2SSB 5263 (chapter 364, Laws of 2023). Washington State Legislature, 2023.
  2. ESSB 5187, 2023-25 operating budget, chapter 475, Laws of 2023, Sec. 606(85). Washington State Legislature, signed May 16, 2023.
  3. ESSB 5167, 2025-27 operating budget, chapter 424, Laws of 2025, Sec. 606(50) and 606(62). Washington State Legislature, signed May 20, 2025.
  4. ESSB 5950, 2024 supplemental budget, chapter 376, Laws of 2024, Sec. 602(103). Washington State Legislature, signed March 29, 2024.
  5. PsiloStudy: Psilocybin With Psychological Support for Military Veterans and First Responders With Co-occurring PTSD and Alcohol Use Disorder (NCT06853912). ClinicalTrials.gov, last updated August 13, 2026; checked November 2, 2026.
  6. Psilocybin clinical trial for Alcohol Use Disorder and PTSD: PsiloStudy. UW Center for Novel Therapeutics in Addiction Psychiatry, page updated June 26, 2026.
  7. Center for Novel Therapeutics in Addiction Psychiatry is official. UW Department of Psychiatry and Behavioral Sciences, March 30, 2023.
  8. Back AL, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, December 2, 2024. PMID 39636638.
  9. A group retreat model for psilocybin therapy in cancer care. Fred Hutch Science Spotlight, March 25, 2026.
  10. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression (PIVOT, NCT07226232). ClinicalTrials.gov, checked November 2, 2026.
  11. Psilocybin studies with a site in Washington State, and the trial records linked in this entry. ClinicalTrials.gov API v2, checked November 2, 2026.
  12. atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results (Exhibit 99.1). atai Life Sciences, filed with the SEC, March 17, 2025.
  13. Reunion Neuroscience: luvesilocin (RE104). Reunion Neuroscience, company site, checked November 2, 2026.
  14. Beug MW, Bigwood J. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A. Journal of Ethnopharmacology, May 1982. PMID 7201053.
  15. Beug, Michael (speaker page). North American Mycological Association, checked November 2, 2026.
  16. Teonanácatl: hallucinogenic mushrooms of North America: extracts from the Second International Conference on Hallucinogenic Mushrooms, held October 27-30, 1977, near Port Townsend, Washington. Madrona Publishers, Seattle, 1978. WorldCat OCLC 4135392.
  17. 42 CFR Part 11, Clinical Trials Registration and Results Information Submission, sections 11.10, 11.44 and 11.64. Electronic Code of Federal Regulations, checked November 2, 2026.
  18. RCW 69.50.204, Schedule I. Washington State Legislature, checked November 2, 2026.

Related entries

Compiled and checked by the Magic Mushrooms Seattle editors. Every fact on this page is dated and links to its source. Found an error? Tell us and we'll correct it in the open, as our editorial standards describe. Magic Mushrooms Seattle is published by the team that runs My Mushroom Dispensary, an online shop. We sell no advertising and nothing on this site.